Click for best price
Cancer Monoclonal Antibody Partnering Terms Agreements Market Size, Share 2022
Monoclonal antibodies are single cell clones of antibodies, a biochemical tool that allows scientists to create antibodies that combine the specificity of specific substances. There are many reasons for the medical community to support the use of monoclonal antibodies in cancer treatment. There are a few clinical trials.
This report contains market size and forecasts of Cancer Monoclonal Antibody Partnering Terms and Agreements in Global, including the following market information:
Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Cancer Monoclonal Antibody Partnering Terms and Agreements market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Asset Purchase Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Cancer Monoclonal Antibody Partnering Terms and Agreements include 3SBio, 4D Pharma, Abbvie, Abzena, Adaptive Biotechnologies, Aeglea BioTherapeutics, Agenus Bio, Ascension and Ascentage Pharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Cancer Monoclonal Antibody Partnering Terms and Agreements companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Segment Percentages, by Type, 2021 (%)
Asset Purchase
Collaborative R&D
Joint Venture
Licensing
Other
Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Segment Percentages, by Application, 2021 (%)
Pharmaceutical Industry
Biotechnology
Medical Care
Education and Research
Other
Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Cancer Monoclonal Antibody Partnering Terms and Agreements revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Cancer Monoclonal Antibody Partnering Terms and Agreements revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
3SBio
4D Pharma
Abbvie
Abzena
Adaptive Biotechnologies
Aeglea BioTherapeutics
Agenus Bio
Ascension
Ascentage Pharma
Aslan Pharma
Telix Pharmaceuticals
Basilea Pharmaceutica
Bavarian Nordic
Baxalta
Bayer
Cantargia
Apollomics
Chiome Bioscience
Clovis Oncology
| Report Attributes |
Report Details |
| Report Title |
Cancer Monoclonal Antibody Partnering Terms and Agreements Market, Global Outlook and Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
106 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Overall Market Size
2.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size: 2021 VS 2028
2.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Cancer Monoclonal Antibody Partnering Terms and Agreements Players in Global Market
3.2 Top Global Cancer Monoclonal Antibody Partnering Terms and Agreements Companies Ranked by Revenue
3.3 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue by Companies
3.4 Top 3 and Top 5 Cancer Monoclonal Antibody Partnering Terms and Agreements Companies in Global Market, by Revenue in 2021
3.5 Global Companies Cancer Monoclonal Antibody Partnering Terms and Agreements Product Type
3.6 Tier 1, Tier 2 and Tier 3 Cancer Monoclonal Antibody Partnering Terms and Agreements Players in Global Market
3.6.1 List of Global Tier 1 Cancer Monoclonal Antibody Partnering Terms and Agreements Companies
3.6.2 List of Global Tier 2 and Tier 3 Cancer Monoclonal Antibody Partnering Terms and Agreements Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Markets, 2021 & 2028
4.1.2 Asset Purchase
4.1.3 Collaborative R&D
4.1.4 Joint Venture
4.1.5 Licensing
4.1.6 Other
4.2 By Type - Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue & Forecasts
4.2.1 By Type - Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, 2017-2022
4.2.2 By Type - Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, 2023-2028
4.2.3 By Type - Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size, 2021 & 2028
5.1.2 Pharmaceutical Industry
5.1.3 Biotechnology
5.1.4 Medical Care
5.1.5 Education and Research
5.1.6 Other
5.2 By Application - Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue & Forecasts
5.2.1 By Application - Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, 2017-2022
5.2.2 By Application - Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, 2023-2028
5.2.3 By Application - Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size, 2021 & 2028
6.2 By Region - Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue & Forecasts
6.2.1 By Region - Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, 2017-2022
6.2.2 By Region - Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, 2023-2028
6.2.3 By Region - Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, 2017-2028
6.3.2 US Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size, 2017-2028
6.3.3 Canada Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size, 2017-2028
6.3.4 Mexico Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, 2017-2028
6.4.2 Germany Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size, 2017-2028
6.4.3 France Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size, 2017-2028
6.4.4 U.K. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size, 2017-2028
6.4.5 Italy Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size, 2017-2028
6.4.6 Russia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size, 2017-2028
6.4.7 Nordic Countries Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size, 2017-2028
6.4.8 Benelux Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, 2017-2028
6.5.2 China Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size, 2017-2028
6.5.3 Japan Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size, 2017-2028
6.5.4 South Korea Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size, 2017-2028
6.5.5 Southeast Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size, 2017-2028
6.5.6 India Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, 2017-2028
6.6.2 Brazil Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size, 2017-2028
6.6.3 Argentina Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, 2017-2028
6.7.2 Turkey Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size, 2017-2028
6.7.3 Israel Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size, 2017-2028
6.7.4 Saudi Arabia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size, 2017-2028
6.7.5 UAE Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size, 2017-2028
7 Players Profiles
7.1 3SBio
7.1.1 3SBio Corporate Summary
7.1.2 3SBio Business Overview
7.1.3 3SBio Cancer Monoclonal Antibody Partnering Terms and Agreements Major Product Offerings
7.1.4 3SBio Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in Global Market (2017-2022)
7.1.5 3SBio Key News
7.2 4D Pharma
7.2.1 4D Pharma Corporate Summary
7.2.2 4D Pharma Business Overview
7.2.3 4D Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Major Product Offerings
7.2.4 4D Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in Global Market (2017-2022)
7.2.5 4D Pharma Key News
7.3 Abbvie
7.3.1 Abbvie Corporate Summary
7.3.2 Abbvie Business Overview
7.3.3 Abbvie Cancer Monoclonal Antibody Partnering Terms and Agreements Major Product Offerings
7.3.4 Abbvie Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in Global Market (2017-2022)
7.3.5 Abbvie Key News
7.4 Abzena
7.4.1 Abzena Corporate Summary
7.4.2 Abzena Business Overview
7.4.3 Abzena Cancer Monoclonal Antibody Partnering Terms and Agreements Major Product Offerings
7.4.4 Abzena Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in Global Market (2017-2022)
7.4.5 Abzena Key News
7.5 Adaptive Biotechnologies
7.5.1 Adaptive Biotechnologies Corporate Summary
7.5.2 Adaptive Biotechnologies Business Overview
7.5.3 Adaptive Biotechnologies Cancer Monoclonal Antibody Partnering Terms and Agreements Major Product Offerings
7.5.4 Adaptive Biotechnologies Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in Global Market (2017-2022)
7.5.5 Adaptive Biotechnologies Key News
7.6 Aeglea BioTherapeutics
7.6.1 Aeglea BioTherapeutics Corporate Summary
7.6.2 Aeglea BioTherapeutics Business Overview
7.6.3 Aeglea BioTherapeutics Cancer Monoclonal Antibody Partnering Terms and Agreements Major Product Offerings
7.6.4 Aeglea BioTherapeutics Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in Global Market (2017-2022)
7.6.5 Aeglea BioTherapeutics Key News
7.7 Agenus Bio
7.7.1 Agenus Bio Corporate Summary
7.7.2 Agenus Bio Business Overview
7.7.3 Agenus Bio Cancer Monoclonal Antibody Partnering Terms and Agreements Major Product Offerings
7.7.4 Agenus Bio Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in Global Market (2017-2022)
7.7.5 Agenus Bio Key News
7.8 Ascension
7.8.1 Ascension Corporate Summary
7.8.2 Ascension Business Overview
7.8.3 Ascension Cancer Monoclonal Antibody Partnering Terms and Agreements Major Product Offerings
7.8.4 Ascension Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in Global Market (2017-2022)
7.8.5 Ascension Key News
7.9 Ascentage Pharma
7.9.1 Ascentage Pharma Corporate Summary
7.9.2 Ascentage Pharma Business Overview
7.9.3 Ascentage Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Major Product Offerings
7.9.4 Ascentage Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in Global Market (2017-2022)
7.9.5 Ascentage Pharma Key News
7.10 Aslan Pharma
7.10.1 Aslan Pharma Corporate Summary
7.10.2 Aslan Pharma Business Overview
7.10.3 Aslan Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Major Product Offerings
7.10.4 Aslan Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in Global Market (2017-2022)
7.10.5 Aslan Pharma Key News
7.11 Telix Pharmaceuticals
7.11.1 Telix Pharmaceuticals Corporate Summary
7.11.2 Telix Pharmaceuticals Business Overview
7.11.3 Telix Pharmaceuticals Cancer Monoclonal Antibody Partnering Terms and Agreements Major Product Offerings
7.11.4 Telix Pharmaceuticals Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in Global Market (2017-2022)
7.11.5 Telix Pharmaceuticals Key News
7.12 Basilea Pharmaceutica
7.12.1 Basilea Pharmaceutica Corporate Summary
7.12.2 Basilea Pharmaceutica Business Overview
7.12.3 Basilea Pharmaceutica Cancer Monoclonal Antibody Partnering Terms and Agreements Major Product Offerings
7.12.4 Basilea Pharmaceutica Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in Global Market (2017-2022)
7.12.5 Basilea Pharmaceutica Key News
7.13 Bavarian Nordic
7.13.1 Bavarian Nordic Corporate Summary
7.13.2 Bavarian Nordic Business Overview
7.13.3 Bavarian Nordic Cancer Monoclonal Antibody Partnering Terms and Agreements Major Product Offerings
7.13.4 Bavarian Nordic Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in Global Market (2017-2022)
7.13.5 Bavarian Nordic Key News
7.14 Baxalta
7.14.1 Baxalta Corporate Summary
7.14.2 Baxalta Business Overview
7.14.3 Baxalta Cancer Monoclonal Antibody Partnering Terms and Agreements Major Product Offerings
7.14.4 Baxalta Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in Global Market (2017-2022)
7.14.5 Baxalta Key News
7.15 Bayer
7.15.1 Bayer Corporate Summary
7.15.2 Bayer Business Overview
7.15.3 Bayer Cancer Monoclonal Antibody Partnering Terms and Agreements Major Product Offerings
7.15.4 Bayer Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in Global Market (2017-2022)
7.15.5 Bayer Key News
7.16 Cantargia
7.16.1 Cantargia Corporate Summary
7.16.2 Cantargia Business Overview
7.16.3 Cantargia Cancer Monoclonal Antibody Partnering Terms and Agreements Major Product Offerings
7.16.4 Cantargia Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in Global Market (2017-2022)
7.16.5 Cantargia Key News
7.17 Apollomics
7.17.1 Apollomics Corporate Summary
7.17.2 Apollomics Business Overview
7.17.3 Apollomics Cancer Monoclonal Antibody Partnering Terms and Agreements Major Product Offerings
7.17.4 Apollomics Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in Global Market (2017-2022)
7.17.5 Apollomics Key News
7.18 Chiome Bioscience
7.18.1 Chiome Bioscience Corporate Summary
7.18.2 Chiome Bioscience Business Overview
7.18.3 Chiome Bioscience Cancer Monoclonal Antibody Partnering Terms and Agreements Major Product Offerings
7.18.4 Chiome Bioscience Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in Global Market (2017-2022)
7.18.5 Chiome Bioscience Key News
7.19 Clovis Oncology
7.19.1 Clovis Oncology Corporate Summary
7.19.2 Clovis Oncology Business Overview
7.19.3 Clovis Oncology Cancer Monoclonal Antibody Partnering Terms and Agreements Major Product Offerings
7.19.4 Clovis Oncology Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in Global Market (2017-2022)
7.19.5 Clovis Oncology Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Opportunities & Trends in Global Market
Table 2. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Drivers in Global Market
Table 3. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Restraints in Global Market
Table 4. Key Players of Cancer Monoclonal Antibody Partnering Terms and Agreements in Global Market
Table 5. Top Cancer Monoclonal Antibody Partnering Terms and Agreements Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Share by Companies, 2017-2022
Table 8. Global Companies Cancer Monoclonal Antibody Partnering Terms and Agreements Product Type
Table 9. List of Global Tier 1 Cancer Monoclonal Antibody Partnering Terms and Agreements Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Cancer Monoclonal Antibody Partnering Terms and Agreements Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application ? Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region ? Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2023-2028
Table 30. 3SBio Corporate Summary
Table 31. 3SBio Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
Table 32. 3SBio Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
Table 33. 4D Pharma Corporate Summary
Table 34. 4D Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
Table 35. 4D Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
Table 36. Abbvie Corporate Summary
Table 37. Abbvie Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
Table 38. Abbvie Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
Table 39. Abzena Corporate Summary
Table 40. Abzena Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
Table 41. Abzena Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
Table 42. Adaptive Biotechnologies Corporate Summary
Table 43. Adaptive Biotechnologies Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
Table 44. Adaptive Biotechnologies Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
Table 45. Aeglea BioTherapeutics Corporate Summary
Table 46. Aeglea BioTherapeutics Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
Table 47. Aeglea BioTherapeutics Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
Table 48. Agenus Bio Corporate Summary
Table 49. Agenus Bio Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
Table 50. Agenus Bio Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
Table 51. Ascension Corporate Summary
Table 52. Ascension Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
Table 53. Ascension Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
Table 54. Ascentage Pharma Corporate Summary
Table 55. Ascentage Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
Table 56. Ascentage Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
Table 57. Aslan Pharma Corporate Summary
Table 58. Aslan Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
Table 59. Aslan Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
Table 60. Telix Pharmaceuticals Corporate Summary
Table 61. Telix Pharmaceuticals Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
Table 62. Telix Pharmaceuticals Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
Table 63. Basilea Pharmaceutica Corporate Summary
Table 64. Basilea Pharmaceutica Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
Table 65. Basilea Pharmaceutica Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
Table 66. Bavarian Nordic Corporate Summary
Table 67. Bavarian Nordic Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
Table 68. Bavarian Nordic Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
Table 69. Baxalta Corporate Summary
Table 70. Baxalta Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
Table 71. Baxalta Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
Table 72. Bayer Corporate Summary
Table 73. Bayer Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
Table 74. Bayer Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
Table 75. Cantargia Corporate Summary
Table 76. Cantargia Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
Table 77. Cantargia Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
Table 78. Apollomics Corporate Summary
Table 79. Apollomics Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
Table 80. Apollomics Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
Table 81. Chiome Bioscience Corporate Summary
Table 82. Chiome Bioscience Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
Table 83. Chiome Bioscience Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
Table 84. Clovis Oncology Corporate Summary
Table 85. Clovis Oncology Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
Table 86. Clovis Oncology Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. Cancer Monoclonal Antibody Partnering Terms and Agreements Segment by Type in 2021
Figure 2. Cancer Monoclonal Antibody Partnering Terms and Agreements Segment by Application in 2021
Figure 3. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in 2021
Figure 8. By Type - Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share, 2017-2028
Figure 9. By Application - Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share, 2017-2028
Figure 10. By Region - Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share, 2017-2028
Figure 11. By Country - North America Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share, 2017-2028
Figure 12. US Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share, 2017-2028
Figure 16. Germany Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
Figure 17. France Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share, 2017-2028
Figure 24. China Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
Figure 28. India Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share, 2017-2028
Figure 30. Brazil Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share, 2017-2028
Figure 33. Turkey Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
Figure 37. 3SBio Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. 4D Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Abbvie Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Abzena Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Adaptive Biotechnologies Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Aeglea BioTherapeutics Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Agenus Bio Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Ascension Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Ascentage Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Aslan Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Telix Pharmaceuticals Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Basilea Pharmaceutica Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Bavarian Nordic Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. Baxalta Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. Bayer Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 52. Cantargia Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 53. Apollomics Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 54. Chiome Bioscience Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 55. Clovis Oncology Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
